TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05536141: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Sponsor: Arcus Biosciences, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 362 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,586,736

Rescue Site Savings

+$3,015,936

Unlock Full NCT05536141 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05536141 Rescue Dossier →